Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

On conventional measures, the company’s shares look cheap. According to FactSet consensus forecasts, Novo trades on around 13 ...

Lower prices for first 10 Part D drugs selected for Medicare price negotiations are set to cut seniors' out-of-pocket costs ...

U.S. President Donald Trump took credit during his White House speech on Wednesday night for reducing gasoline prices, ...

Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.

Stephen Colbert wonders why 'The Late Show' was canceled if Paramount has $108 billion to offer for Warner Bros. Skydiver ...

Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates that ...

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

President Trump launched TrumpRx, a new initiative aiming to slash prescription drug costs by forging direct deals with ...